Your browser doesn't support javascript.
loading
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
Jacques, Sarah K; McKeown, Janet; Grover, Piyush; Johnson, Douglas B; Zaremba, Anne; Dimitriou, Florentia; Weiser, Roi; Farid, Mohamad; Namikawa, Kenjiro; Sullivan, Ryan J; Rutkowski, Piotr; Lebbe, Celeste; Hamid, Omid; Zager, Jonathan S; Michielin, Olivier; Neyns, Bart; Nakamura, Yasuhiro; Robert, Caroline; Mehnert, Janice; Ascierto, Paolo A; Bhave, Prachi; Park, Benjamin; Zimmer, Lisa; Mangana, Joanna; Mooradian, Megan; Placzke, Joanna; Allayous, Clare; Glitza Oliva, Isabella C; Mehmi, Inderjit; Depalo, Danielle; Wicky, Alexandre; Schwarze, Julia K; Roy, Severine; Boatwright, Christina; Vanella, Vito; Long, Georgina V; Menzies, Alexander M; Lo, Serigne N; Carlino, Matteo S.
Afiliação
  • Jacques SK; Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, Australia.
  • McKeown J; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Grover P; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Johnson DB; Vanderbilt University Medical Centre, Nashville, TN, USA.
  • Zaremba A; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany.
  • Dimitriou F; Department of Dermatology, University Hospital of Zurich and Faculty of Medicine, University of Zürich, Zurich, Switzerland.
  • Weiser R; MD Anderson Cancer Center, Houston, TX, USA.
  • Farid M; National Cancer Centre, Singapore.
  • Namikawa K; Department of Dermatologic Oncology, National Cancer Center, Tokyo, Japan.
  • Sullivan RJ; Massachusetts General Hospital, Harvard University, Boston, MA, USA.
  • Rutkowski P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Lebbe C; Université Paris Cite,AP-HP Dermato-oncology, Cancer institute APHP.nord Paris cité, INSERM U976, Saint Louis Hospital, Paris, France.
  • Hamid O; The Angeles Clinic, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.
  • Zager JS; Department of Cutaneous Oncology, Moffit Cancer Center, Tampa, FL, USA.
  • Michielin O; Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
  • Neyns B; Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Nakamura Y; Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
  • Robert C; Institute Gustave Roussy and Paris Saclay University, Villejuif Cedex, France.
  • Mehnert J; NYU Langone, New York City, NY, USA.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
  • Bhave P; Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Park B; Vanderbilt University Medical Centre, Nashville, TN, USA.
  • Zimmer L; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany.
  • Mangana J; Department of Dermatology, University Hospital of Zurich and Faculty of Medicine, University of Zürich, Zurich, Switzerland.
  • Mooradian M; Massachusetts General Hospital, Harvard University, Boston, MA, USA.
  • Placzke J; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Allayous C; Université Paris Cite,AP-HP Dermato-oncology, Cancer institute APHP.nord Paris cité, INSERM U976, Saint Louis Hospital, Paris, France.
  • Glitza Oliva IC; MD Anderson Cancer Center, Houston, TX, USA.
  • Mehmi I; The Angeles Clinic, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.
  • Depalo D; Department of Cutaneous Oncology, Moffit Cancer Center, Tampa, FL, USA.
  • Wicky A; Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
  • Schwarze JK; Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Roy S; Institute Gustave Roussy and Paris Saclay University, Villejuif Cedex, France.
  • Boatwright C; NYU Langone, New York City, NY, USA.
  • Vanella V; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
  • Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia.
  • Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
  • Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Carlino MS; Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia. Electronic address: matteo.carlino@sydney.edu.au.
Eur J Cancer ; 199: 113563, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38278007
ABSTRACT
IMPORTANCE Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma.

OBJECTIVE:

To determine the efficacy of adjuvant PD1 in resected AM or MM.

DESIGN:

An international, retrospective cohort study

SETTING:

Data up to November 2021 collected from 20 centres across 10 countries.

PARTICIPANTS:

One hundred and ninety four patients with resected stage III or IV1 AM or MM who received adjuvant PD1 were included and compared to matched patients from the Melanoma Institute Australia (MIA) database using a propensity score matching analysis. MAIN OUTCOMES AND

MEASURES:

Recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) were investigated.

RESULTS:

Forty five of 139 (32%) AM and 9 of 55 (16%) MM patients completed adjuvant therapy. The main reason for early treatment cessation in both groups was disease recurrence 51 (37%) and 30 (55%) in the AM and MM groups, respectively. In the AM group adjuvant PD1 was associated with a longer RFS [HR-0.69 (0.52-0.92, p = 0.0127)], DMFS [HR0.58 (0.38-0.89, p = 0.0134)] and OS [HR of 0.59 (0.38-0.92, p-value 0.0196)] when compared to the historical cohort. In the MM group there was no statistical difference in RFS [HR1.36 (0.69-2.68,p-value 0.3799], DMFS or OS. CONCLUSION AND RELEVANCE After adjuvant PD1, both AM and MM have a high risk of recurrence. Our data suggests a benefit to using adjuvant PD1 therapy in resected AM but not in resected MM. Additional studies to investigate the efficacy of adjuvant PD1 for MM are needed.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália